• Vol. 48 No. 4, 133–138
  • 15 April 2019

HLA-B*5701 Genotyping for Abacavir Prescription: Re-Examination of its Cost-Effectiveness in Singapore


Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) that is used to control disease progression of human immunodeficiency viruses (HIV). It reduces the morbidity and mortality of HIV infections.1 A serious side effect of abacavir is hypersensitivity reaction (HSR) which usually begins within 6 weeks of starting treatment and manifests as fever, malaise, nausea, vomiting and rashes. In severe cases, it results in multiple organ system failure.

This article is available only as a PDF. Please click on “Download PDF” on top to view the full article.